These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

926 related items for PubMed ID: 12733143

  • 1. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM.
    Cancer; 2003 May 15; 97(10):2440-52. PubMed ID: 12733143
    [Abstract] [Full Text] [Related]

  • 2. [Relation of serum levels of the soluble cytoadhesion molecules sVCAM-1 and sICAM-1 to selected factors in the cytokine network in multiple myeloma].
    Scudla V, Budíková M, Bacovský J, Opíchalová D, Farbiaková V.
    Cas Lek Cesk; 2000 Jul 05; 139(13):401-6. PubMed ID: 10971970
    [Abstract] [Full Text] [Related]

  • 3. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H, Wiersbowska A, Stepień H, Robak T.
    Eur Cytokine Netw; 2000 Sep 05; 11(3):443-51. PubMed ID: 11022130
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prognostic factors in multiple myeloma.
    Kyle RA.
    Stem Cells; 1995 Aug 05; 13 Suppl 2():56-63. PubMed ID: 8520513
    [Abstract] [Full Text] [Related]

  • 6. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma.
    Stasi R, Brunetti M, Parma A, Di Giulio C, Terzoli E, Pagano A.
    Cancer; 1998 May 15; 82(10):1860-6. PubMed ID: 9587117
    [Abstract] [Full Text] [Related]

  • 7. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
    Spicka I, Cieslar P, Procházka B, Jirsa M, Chrz M, Gregora E, Klener P.
    Cas Lek Cesk; 2000 Apr 12; 139(7):208-12. PubMed ID: 10916207
    [Abstract] [Full Text] [Related]

  • 8. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS.
    Ann Hematol; 2003 Jan 12; 82(1):19-23. PubMed ID: 12574959
    [Abstract] [Full Text] [Related]

  • 9. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
    Kuku I, Bayraktar MR, Kaya E, Erkurt MA, Bayraktar N, Cikim K, Aydogdu I.
    Mediators Inflamm; 2005 Aug 14; 2005(3):171-4. PubMed ID: 16106104
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H, Wierzbowska A, Robak T.
    Eur Cytokine Netw; 2003 Aug 14; 14(1):40-51. PubMed ID: 12799213
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
    Gaillard JP, Liautard J, Klein B, Brochier J.
    Eur J Immunol; 1997 Dec 14; 27(12):3332-40. PubMed ID: 9464821
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cytokine network in human multiple myeloma.
    Klein B, Bataille R.
    Hematol Oncol Clin North Am; 1992 Apr 14; 6(2):273-84. PubMed ID: 1582974
    [Abstract] [Full Text] [Related]

  • 16. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P, Kamińska J, Kowalska M, Ruka W, Steffen J.
    J Surg Oncol; 2003 Nov 14; 84(3):151-9. PubMed ID: 14598359
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data.
    Lauta VM.
    Cytokine; 2001 Nov 07; 16(3):79-86. PubMed ID: 11741345
    [Abstract] [Full Text] [Related]

  • 19. Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage.
    Thabard W, Barillé S, Collette M, Harousseau JL, Rapp MJ, Bataille R, Amiot M.
    Clin Cancer Res; 1999 Oct 07; 5(10):2693-7. PubMed ID: 10537331
    [Abstract] [Full Text] [Related]

  • 20. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
    Kim SY, Min HJ, Park HK, Oh B, Kim TY, She CJ, Hwang SM, Kim M, Kim HK, Kim I, Yoon SS, Park S, Kim BK, Lee JH, Lee DS, Korea Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2011 Jun 07; 17(6):810-20. PubMed ID: 21220034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.